A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Drug Therapy, Combination, Zidovudine, HIV Protease Inhibitors, Lamivudine, VX 478, Reverse Transcriptase Inhibitors, Anti-HIV Agents, Viral Load
Eligibility Criteria
Inclusion Criteria Patients must have: HIV-positive status. Screening viral load >= 10,000 copies/mm3 14 days prior to entry. CD4+ cell counts >= 200 cells/mm3 14 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinical diagnosis of AIDS (CDC 1993 Classification C). Concurrent Medication: Excluded: Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens. Patients with the following prior conditions are excluded: Clinically relevant hepatitis in the previous 6 months. Prior Medication: Excluded: Greater than 4 weeks of any nucleoside antiretroviral therapy. Previous therapy with an HIV protease inhibitor. Cytotoxic chemotherapeutic agents within 4 weeks prior to entry. Immunomodulating agents within 3 months prior to entry. Prior Treatment: Excluded: Radiotherapy within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.
Sites / Locations
- Pacific Oaks Research
- Dr Bruce Rashbaum
- Community Research Initiative of South Florida
- Community Research Initiative of Central Florida
- Univ of Miami School of Medicine
- Chicago Ctr for Clinical Research
- Community Research Initiative of New England
- Saint Vincent's AIDS Ctr
- Methodist Hosp